» Authors » Raluca Munteanu

Raluca Munteanu

Explore the profile of Raluca Munteanu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 120
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Tigu A, Munteanu R, Moldovan C, Rares D, Kegyes D, Tomai R, et al.
Cell Death Discov . 2024 Nov; 10(1):471. PMID: 39551787
Receptor tyrosine kinases (RTKs) are key cell surface receptors involved in cell communication and signal transduction, with great importance in cell growth, differentiation, survival, and metabolism. Dysregulation of RTKs, such...
2.
Gulei D, Moisoiu V, Kegyes D, Drula R, Iluta S, Tigu A, et al.
J Cell Mol Med . 2024 Sep; 28(18):e70078. PMID: 39334509
Myelodysplastic syndromes (MDS) are myeloid malignancies with heterogeneous genotypes and phenotypes, characterized by ineffective haematopoiesis and a high risk of progression towards acute myeloid leukaemia (AML). Prognosis for patients treated...
3.
Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A, et al.
Signal Transduct Target Ther . 2024 Aug; 9(1):201. PMID: 39138146
Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained significant clinical attention in oncology due to their central role in cancer pathogenesis. Genetic alterations, including mutations, amplifications, and...
4.
Barar A, Pralea I, Maslyennikov Y, Munteanu R, Berindan-Neagoe I, Pirlog R, et al.
Int J Mol Sci . 2024 Jun; 25(11). PMID: 38891801
The mechanism underlying podocyte dysfunction in minimal change disease (MCD) remains unknown. This study aimed to shed light on the potential pathophysiology of MCD using glomerular proteomic analysis. Shotgun proteomics...
5.
Munteanu R, Tomuleasa C, Iuga C, Gulei D, Ciuleanu T
Cancers (Basel) . 2023 Nov; 15(22). PMID: 38001653
Lung cancer, primarily non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC), is distinguished by its high prevalence and marked mortality rates. Traditional therapeutic approaches, encompassing chemotherapy, radiation,...
6.
Cismaru C, Tomuleasa C, Jurj A, Chira S, Isachekcu E, Cismaru G, et al.
Stem Cell Rev Rep . 2023 Nov; 20(1):206-217. PMID: 37922107
Strategies to improve hematopoietic stem and progenitor cell (HSPC) mobilization from the bone marrow can have a pivotal role in addressing iatrogenic bone-marrow insufficiency from chemo(radio)therapy and overcoming peripheral blood...
7.
Tigu A, Constantinescu C, Teodorescu P, Kegyes D, Munteanu R, Feder R, et al.
J Cell Mol Med . 2023 Sep; 27(19):2864-2875. PMID: 37667538
Acute megakaryoblastic leukaemia (AMkL) is a rare subtype of acute myeloid leukaemia (AML) representing 5% of all reported cases, and frequently diagnosed in children with Down syndrome. Patients diagnosed with...
8.
Munteanu R, Feder R, Onaciu A, Munteanu V, Iuga C, Gulei D
Cancers (Basel) . 2023 May; 15(9). PMID: 37174009
The human microbiome represents the diversity of microorganisms that live together at different organ sites, influencing various physiological processes and leading to pathological conditions, even carcinogenesis, in case of a...
9.
Iluta S, Pasca S, Gafencu G, Jurj A, Terec A, Teodorescu P, et al.
J Cell Mol Med . 2021 Jun; 25(13):6094-6102. PMID: 34132464
Patients with relapsed/refractory acute myeloid leukaemia (AML), ineligible for intensive chemotherapy and allogeneic stem cell transplantation, have a dismal prognosis. For such cases, hypomethylating agents are a viable alternative, but...
10.
Cenariu D, Zimta A, Munteanu R, Onaciu A, Moldovan C, Jurj A, et al.
Pharmaceutics . 2021 Jun; 13(5). PMID: 34066331
Colon cancer is the third most common cancer type worldwide and is highly dependent on DNA mutations that progressively appear and accumulate in the normal colon epithelium. Mutations in the...